5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman is a chemical compound which belongs to the family of ergot alkaloids. While this compound may seem esoteric to the average individual, it has significant relevance in various aspects of everyday life.
For example, derivatives of ergot alkaloids like 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman have been utilized in the pharmaceutical industry to develop medications for conditions such as migraines, Parkinson’s disease, and restless leg syndrome, among others. Furthermore, these compounds have also been investigated for their potential role in the treatment of psychiatric disorders such as schizophrenia and depression.
Additionally, ergot alkaloids have historically been used in agriculture as pesticides and growth regulators. Their vasoconstrictive properties have also made them valuable in the field of medicine for controlling bleeding during surgery.
In conclusion, while the compound 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman may not be a household name, its derivatives and related ergot alkaloids play a critical role in several industries and have a notable impact on everyday life through their various applications and potential therapeutic benefits.
Table of Contents:
- 💡 Commercial Applications
- ⚗️ Chemical & Physical Properties
- 🏭 Production & Procurement
- ⚠️ Safety Considerations
- 🔬 Potential Research Directions
- 🧪 Related Compounds
💡 Commercial Applications
5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman, commonly known as ergotamine, has several commercial and industrial applications. This compound is primarily used in the pharmaceutical industry to produce medications for the treatment of migraines and cluster headaches. Additionally, ergotamine is utilized in research laboratories for studying the effects of ergot alkaloids on the central nervous system.
In terms of drug and medication applications, ergotamine is a key ingredient in various medications prescribed to alleviate symptoms of migraine headaches. This compound works by constricting blood vessels in the brain, thereby reducing the throbbing pain associated with migraines. It is commonly administered in oral, sublingual, or suppository forms, depending on the severity of the headache and the patient’s preference.
Ergotamine is also used in the formulation of medications to treat postpartum hemorrhage, a potentially life-threatening condition that occurs after childbirth. By promoting uterine contractions, ergotamine helps to control excessive bleeding and prevent further complications. This usage underscores the diverse therapeutic applications of ergotamine in the field of medicine.
⚗️ Chemical & Physical Properties
5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman is a white, crystalline solid with no distinct odor. Its appearance is reminiscent of powdered sugar, though it lacks any sweetness in its smell.
The molar mass of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman is approximately 581.7 g/mol, with a density of around 1.4 g/cm³. This places it in line with common food items such as sugar in terms of molar mass, but it is much denser compared to substances like water.
The compound has a high melting point of about 230°C and a boiling point around 700°C. This sets it apart from most common food items, which typically have lower melting and boiling points, such as butter or chocolate.
5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman is sparingly soluble in water and exhibits a high viscosity. Its solubility in water is much lower than common food items like table salt, while its viscosity is higher compared to substances like olive oil.
🏭 Production & Procurement
Paragraph 1: 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman is a complex molecule that is typically produced through a multi-step chemical synthesis process in a controlled laboratory setting. The synthesis involves the manipulation of various chemical reagents and catalysts to sequentially build up the molecular structure of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman.
Paragraph 2: Procuring 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman usually involves contacting a specialized chemical supplier or manufacturer who has the capability to produce this compound. Once the compound is synthesized, it can be transported via specialized chemical handling procedures to ensure its stability and integrity during transit to the end user or researcher seeking to utilize it for various medicinal or scientific applications.
Paragraph 3: Due to the sensitive nature of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman, it is important to store and transport the compound in suitable conditions to prevent degradation or contamination. Proper labeling and handling instructions should be followed to ensure the safety of those working with or in proximity to the compound. Additionally, regulatory guidelines may apply to the production, procurement, and transport of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman to ensure compliance with legal requirements.
⚠️ Safety Considerations
Safety considerations for 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman should be taken very seriously due to its potential hazards. This compound may cause skin irritation, eye irritation, respiratory irritation, and harm to aquatic life. Proper protective equipment such as gloves, goggles, and a lab coat should be worn when handling this substance to minimize the risk of exposure.
Additionally, appropriate measures should be taken to prevent environmental contamination, such as proper disposal methods and avoiding release into the environment. It is crucial to work with 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman in a well-ventilated area to reduce the risk of inhalation exposure. In case of accidental exposure, immediate medical attention should be sought, and the SDS (Safety Data Sheet) should be consulted for guidance on the proper response.
Hazard statements for 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman include causing skin irritation, eye irritation, and respiratory irritation. This compound may also be harmful if swallowed or if it comes into contact with aquatic organisms. It is essential to handle this substance with care and to follow all safety protocols to minimize the risk of harm to oneself and the environment.
Precautionary statements for 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman include wearing protective gloves, clothing, and eye protection when handling this compound. Avoid releasing it into the environment and dispose of it properly according to regulations. In case of accidental exposure, seek medical advice immediately. Store 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman in a cool, dry place away from incompatible materials. Regularly review the SDS for updated information on handling and storage.
🔬 Potential Research Directions
Research on 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman could explore its potential therapeutic applications in the treatment of neurological disorders or psychiatric conditions. Investigations into its mechanism of action and pharmacological properties could provide valuable insights for drug development.
Further studies may focus on the synthesis and modification of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman derivatives to improve its potency, selectivity, and pharmacokinetic profile. These efforts could lead to the development of novel drugs with enhanced efficacy and reduced side effects for the targeted conditions.
Exploration of the structure-activity relationship of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman analogs could help in identifying key structural features crucial for its biological activity. This knowledge could guide medicinal chemists in designing more potent and specific compounds with improved therapeutic potential.
Investigations into the metabolism, distribution, and excretion of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman in preclinical and clinical studies could provide important data on its safety profile and dosage regimen. Understanding its pharmacokinetic properties is essential for optimizing drug delivery and ensuring patient safety in clinical practice.
Additionally, research could explore the interactions of 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman with other drugs or endogenous molecules, to assess potential drug-drug interactions or toxicities. This knowledge could help in the rational design of combination therapies and personalized treatment approaches for patients with complex medical conditions.
🧪 Related Compounds
One similar compound to 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotaman is 5′-Benzyl-12′-hydroxy-2′-ethyl-3′,6′,18-trioxoergotaman. In this compound, the methyl group at the 2′ position has been replaced with an ethyl group, resulting in a slightly different molecular structure. This substitution may lead to changes in the compound’s physicochemical properties and biological activities.
Another similar compound is 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-trioxoergotamin. In this compound, the last “a” in “-aman” has been changed to an “in,” creating a different naming convention. This change might reflect a variation in the pharmacological or biochemical characteristics of the compound, warranting further investigation to determine its implications.
A third related compound is 5′-Benzyl-12′-hydroxy-2′-methyl-3′,6′,18-dioxoergotaman. In this compound, the trioxoergotaman structure has been modified to dioxoergotaman, indicating a reduction in the number of ketone groups present in the molecule. This alteration could potentially affect the compound’s reactivity or interaction with biological targets.
